CDKN2A and glioblastoma: Glioblastoma sequence alterations markers typically include p-TERT mutations, loss of cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) and phosphatase and tensin homolog (PTEN), amplification or truncation of epidermal growth factor receptor (EGFR), TP53 pathogenic variants, as well as large chromosomal aberrations — 10 chromosome loss, 7 chromosome gain (chr +7/-10) (Figure 1).